2026-06-14T00:27:46Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/180592024-02-12T19:46:25Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927
Repisalud author Abuín-Fernández, Jose author Tapia-Guerrero, María José author López-Urdiales, Rafael author Herranz-Antolín, Sandra author García-Almeida, Jose Manuel author García-Malpartida, Katherine author Ferrer-Gómez, Mercedes author Cancer-Minchot, Emilia author Luengo-Pérez, Luis Miguel author Álvarez-Hernández, Julia author Valera, Carmen Aragón author Ocón-Bretón, Julia author García-Manzanares, Álvaro author Bretón-Lesmes, Irene author Serrano-Aguayo, Pilar author Pérez-Ferre, Natalia author López-Gómez, Juan José author Olivares-Alcolea, Josefina author Arraiza-Irigoyen, Carmen author Tejera-Pérez, Cristina author Martínez-González, Jorge Daniel author Urioste-Fondo, Ana author Abad-González, Ángel Luis author Molina-Puerta, María José author Zugasti-Murillo, Ana author Parra-Barona, Juan author López-Cobo, Irela author Olveira-Fuster, And Gabriel 2024-02-12T19:46:25Z 2024-02-12T19:46:25Z 2020-05-27 10.3390/nu12061566 2072-6643 Nutrients http://hdl.handle.net/10668/15660 32471262 http://hdl.handle.net/20.500.12105/18059 There are no studies that have specifically assessed the role of intravenous lipid emulsions (ILE) enriched with fish oil in people with diabetes receiving total parenteral nutrition (TPN). The objective of this study was to assess the metabolic control (glycemic and lipid) and in-hospital complications that occurred in non-critically ill inpatients with TPN and type 2 diabetes with regard to the use of fish oil emulsions compared with other ILEs. We performed a post-hoc analysis of the Insulin in Parenteral Nutrition (INSUPAR) trial that included patients who started with TPN for any cause and that would predictably continue with TPN for at least five days. The study included 161 patients who started with TPN for any cause. There were 80 patients (49.7%) on fish oil enriched ILEs and 81 patients (50.3%) on other ILEs. We found significant decreases in triglyceride levels in the fish oil group compared to the other patients. We did not find any differences in glucose metabolic control: mean capillary glucose, glycemic variability, and insulin dose, except in the number of mild hypoglycemic events that was significantly higher in the fish oil group. We did not observe any differences in other metabolic, liver or infectious complications, in-hospital length of stay or mortality. eng Hospital Omega 3 Parenteral nutrition Polyunsaturated fatty acids Type 2 diabetes mellitus Fish Oil Enriched Intravenous Lipid Emulsions Reduce Triglyceride Levels in Non-Critically Ill Patients with TPN and Type 2 Diabetes. A Post-Hoc Analysis of the INSUPAR Study. research article